US Bancorp’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.87K | Buy |
392
+26
| +7% | +$349 | ﹤0.01% | 3582 |
|
|
2025
Q4 | $4.61K | Hold |
366
| – | – | ﹤0.01% | 3564 |
|
|
2025
Q3 | $3.66K | Sell |
366
-118
| -24% | -$1.06K | ﹤0.01% | 3623 |
|
|
2025
Q2 | $3.92K | Buy |
484
+15
| +3% | +$113 | ﹤0.01% | 3710 |
|
|
2025
Q1 | $3.93K | Buy |
469
+197
| +72% | +$1.64K | ﹤0.01% | 3724 |
|
|
2024
Q4 | $2.15K | Buy |
272
+118
| +77% | +$990 | ﹤0.01% | 3843 |
|
|
2024
Q3 | $1.28K | Hold |
154
| – | – | ﹤0.01% | 3863 |
|
|
2024
Q2 | $978 | Hold |
154
| – | – | ﹤0.01% | 3813 |
|
|
2024
Q1 | $933 | Sell |
154
-443
| -74% | -$2.5K | ﹤0.01% | 3821 |
|
|
2023
Q4 | $3.62K | Buy |
597
+494
| +480% | +$2.2K | ﹤0.01% | 3600 |
|
|
2023
Q3 | $435 | Sell |
103
-1,682
| -94% | -$6.27K | ﹤0.01% | 3862 |
|
|
2023
Q2 | $5.53K | Buy |
1,785
+458
| +35% | +$976 | ﹤0.01% | 3454 |
|
|
2023
Q1 | $1.84K | Hold |
1,327
| – | – | ﹤0.01% | 3774 |
|
|
2022
Q4 | $2.64K | Buy |
1,327
+1,209
| +1,025% | +$2.71K | ﹤0.01% | 3702 |
|
|
2022
Q3 | $0 | Sell |
118
-5,815
| -98% | -$16.3K | ﹤0.01% | 4054 |
|
|
2022
Q2 | $19K | Buy |
5,933
+5,111
| +622% | +$18.5K | ﹤0.01% | 3061 |
|
|
2022
Q1 | $3K | Sell |
822
-59
| -7% | -$261 | ﹤0.01% | 3712 |
|
|
2021
Q4 | $4K | Sell |
881
-308
| -26% | -$1.54K | ﹤0.01% | 3691 |
|
|
2021
Q3 | $7K | Buy |
1,189
+116
| +11% | +$584 | ﹤0.01% | 3543 |
|
|
2021
Q2 | $5K | Sell |
1,073
-368
| -26% | -$2.09K | ﹤0.01% | 3598 |
|
|
2021
Q1 | $10K | Buy |
1,441
+619
| +75% | +$3.43K | ﹤0.01% | 3271 |
|
|
2020
Q4 | $4K | Hold |
822
| – | – | ﹤0.01% | 3427 |
|
|
2020
Q3 | $3K | Sell |
822
-1,500
| -65% | -$6.42K | ﹤0.01% | 3391 |
|
|
2020
Q2 | $11K | Hold |
2,322
| – | – | ﹤0.01% | 3057 |
|
|
2020
Q1 | $8K | Buy |
2,322
+1,830
| +372% | +$7.75K | ﹤0.01% | 3078 |
|
|
2019
Q4 | $2K | Sell |
492
-142
| -22% | -$494 | ﹤0.01% | 3454 |
|
|
2019
Q3 | $2K | Buy |
634
+492
| +346% | +$1.72K | ﹤0.01% | 3392 |
|
|
2019
Q2 | $1K | Sell |
142
-1,610
| -92% | -$16.5K | ﹤0.01% | 3527 |
|
|
2019
Q1 | $25K | Buy |
1,752
+105
| +6% | +$1.39K | ﹤0.01% | 2768 |
|
|
2018
Q4 | $22K | Sell |
1,647
-247
| -13% | -$4.45K | ﹤0.01% | 2775 |
|
|
2018
Q3 | $42K | Buy |
1,894
+18
| +1% | +$379 | ﹤0.01% | 2643 |
|
|
2018
Q2 | $31K | Buy |
+1,876
| New | +$32.9K | ﹤0.01% | 2782 |
|
Other funds holding AMRX
TGA
VPM
RCMNY
VCM
US Bancorp's AMRX Position: Q1 2026 in Review
US Bancorp increased its Amneal Pharmaceuticals (AMRX) stake by 7.1% in Q1 2026, buying an estimated $349 and bringing the position to 392 shares worth $4.87K. The position accounts for ﹤0.01% of the portfolio, ranked #3582.
US Bancorp first reported a position in AMRX in Q2 2018 and has held it in 32 quarters since. The position peaked at $42K in Q3 2018. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.
- US Bancorp held 392 shares of Amneal Pharmaceuticals worth $4.87K as of Q1 2026.
- US Bancorp bought 26 Amneal Pharmaceuticals shares in Q1 2026, an estimated $349.
- Amneal Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3582 holding.
- US Bancorp first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- US Bancorp's Amneal Pharmaceuticals position peaked at $42K in Q3 2018.
- 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.
Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.